Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"BiomX","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"company":"BiomX","sponsor":"Maruho","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"BiomX"},{"company":"Kamari Pharma","sponsor":"GIBF2","pharmaFlowCategory":"D","amount":"$8.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Undisclosed","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Kamari Pharma"}]

Kamari Pharma

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Kamari Pharma Raises $8 Million from the Sino-Israeli GIBF2 Fund

Details:

The company develops topical and oral drugs based on proprietary small molecules that inhibit an ion channel designated TRPV3. These drugs are intended for the treatment of various dermatological diseases.

Lead Product(s): Undisclosed

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: GIBF2

Deal Size: $8.0 million Upfront Cash: Undisclosed

Deal Type: Financing September 19, 2022

ASK
US

Upload
your Pipeline Activity

BiomX

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

BiomX Announces Agreement with Maruho Co., Ltd. for Atopic Dermatitis Product Candidate BX005

Details:

Maruho also entered into a binding agreement for an equity investment in BiomX of $3 million at a premium to the market share price, intended primarily to support the Phase 1/2 study of atopic dermatitis product candidate, BX005, in Japan.

Lead Product(s): BX005

Therapeutic Area: Dermatology Product Name: BX005

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Maruho

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement October 13, 2021

ASK
US

Upload
your Pipeline Activity

BiomX

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

BiomX Presents Preclinical Results With BX005 for Atopic Dermatitis at the Revolutionizing Atopic Dermatitis

Details:

In vitro results with BX005 demonstrated a broad host range and efficient eradication of Staphylococcus aureus strains with no mutants arising after 24 hours, versus untreated strains showing normal growth.

Lead Product(s): BX005

Therapeutic Area: Dermatology Product Name: BX005

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2021

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY